Therapy for Mild to Moderate Asthma.

of the Clinical Problem Asthma is a disease characterized by recurring, reversible airways obstruction due to underlying inflammation and bronchial hyperresponsiveness. Asthma is one of the most common chronic noncommunicable diseases, affects an estimated 260 million people globally, and is associated with significant morbidity and mortality.1 Asthma with usually mild or infrequent symptoms (50%-75% of patients with asthma) contributes to 30% to 40% of exacerbations leading to emergency care; asthma-related death may occur in persons with asthma that is usually mild.2

[1]  A. Borgmeyer,et al.  School Nurse Knowledge of 2020 Focused Updates to the Asthma Management Guidelines , 2024, Journal of Allergy and Clinical Immunology.

[2]  K. Lavoie,et al.  Asthma patients' and physicians' perspectives on the burden and management of asthma. , 2021, Respiratory medicine.

[3]  Navid Rabiee,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[4]  I. Pavord,et al.  Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. , 2019, The New England journal of medicine.

[5]  Meilan K. Han,et al.  Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy Statement , 2018, American journal of respiratory and critical care medicine.

[6]  A. Goldsobel Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis , 2018, Pediatrics.

[7]  E. Bateman,et al.  As‐Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma , 2018, The New England journal of medicine.

[8]  E. Bateman,et al.  Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma , 2018, The New England journal of medicine.

[9]  C. White,et al.  Association of Inhaled Corticosteroids and Long-Acting &bgr;-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis , 2018, JAMA.

[10]  M. Schatz,et al.  Short-acting β-agonist use and its ability to predict future asthma-related outcomes. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  C. Delacourt,et al.  Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations , 2007, Allergy.

[12]  R. Pauwels,et al.  Low-dose inhaled corticosteroids and the prevention of death from asthma. , 2000, The New England journal of medicine.